Search for European Projects

11 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Children’s Liver Tumour European Research Network (ChiLTERN)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying ...
Read Project

 21

 FINISHED 

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Read Project

 49

 FINISHED 

Eliciting Mucosal Immunity to Tuberculosis (EMI-TB)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis ...
Read Project

 15

 FINISHED 

Towards the elimination of iodine deficiency and preventable thyroid-related diseases in Europe (EUthyroid)

Start date: Jun 1, 2015, End date: May 31, 2018,

Despite the fact that iodine deficiency (ID) can easily be prevented by iodine fortification of table salt, industrial salt and cattle food, Europe belongs to the worst regions in terms of access to iodized salt and is seriously ID, resulting in the perpetuation of the single most important, preventable cause of brain damage. European ID is due to significant heterogeneity in prevention and monito ...
Read Project

 33

 FINISHED 

A progress of tuberculosis and HIV/tuberculosis treatment assessed by fingerprinting of small molecule-biomarkers in patients from Eastern Europe (TB prognosis)

Start date: Apr 1, 2013, End date: Mar 31, 2017,

A dramatically high incidence of multidrug-resistant (MDR) and extended drug resistant (XDR) tuberculosis (TB) was reported in WHO European Region. Countries in Eastern Europe still fail to control TB and in, for example, Ukraine, a number of new TB cases is as high as 100-299 per 100 000 (data for 2010). TB is often accompanied by HIV on this territory. In EU countries, patients with MDR and XDR- ...
Read Project

 2

 FINISHED 

Identifying new Markers and Homing Profiles involved in Lymphocyte Migration to the Female Reproductive Tract (FRT-homing)

Start date: Apr 1, 2012, End date: Sep 17, 2016,

The effort to develop vaccines that can elicit mucosal immune responses in the female reproductive tract (FRT) against sexually transmitted infections (STI) have been hampered by an inability to accurately measure immune responses in the genital tract. Vaccines against STIs should generate localized memory responses at sites of potential exposure to provide better control of infection. Critically, ...
Read Project

 1

 FINISHED 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Start date: Jan 1, 2010, End date: Feb 28, 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Read Project

 39

 FINISHED 

Compliance and effectiveness in HF and CHD closed-loop management (HeartCycle)

Start date: Mar 1, 2008, End date: Aug 31, 2013,

Each year Cardiovascular Disease (CVD) causes over 1.9 million deaths in the EU, causing direct health costs of €105 billion. Coronary Heart Disease (CHD), half of all CVD deaths, is the single most cause of death in Europe. Heart Failure (HF) – a CHD being the most frequent cause of hospitalization for people over 65 – has 10 million patients in the EU. Current treatment of HF entails recommendat ...
Read Project

 22

 FINISHED 

Novel strategies for the prevention and control of persistent infections (NOPERSIST)

Start date: Jan 1, 2010, End date: Dec 31, 2012,

"Persistent infections such as HIV, tuberculosis´(TB) in humans and para-tuberculosis (ParaTB)-, mycoplasma- and Haemophilus-infections in farm animals are global health problems of immense social and economic importance . HIV-1 affects about 40 million people and M. tuberculosis infection is even higher world-wide. Co-infection with M. tuberculosis is estimated in about one-third of HIV-1 infecte ...
Read Project

 12

 FINISHED 

Regeneration of Cardiac Tissue Assisted by Bioactive Implants (RECATABI)

Start date: Jan 1, 2010, End date: Dec 31, 2012,

Heart failure is the end-stage of many cardiovascular diseases, but the leading cause is the presence of a large scar due acute to myocardial infarction. Current therapeutic treatments under development consist in cellular cardiomyoplasty where myocardial cells or stem cells are implanted alone or encapsulated in natural scaffolds (collagens) and grafted onto infarcted ventricles with the hope tha ...
Read Project

 7

 FINISHED 

LATENT TUBERCULOSIS: New tools for the detection and clearance of dormant Mycobacterium tuberculosis (STOPLATENT-TB)

Start date: Feb 1, 2008, End date: Jul 31, 2011,

Although the definition of latency under a clinical point of view seems clear, the bacterial biology behind that clinical situation remains poorly understood. While dormant, the tubercle bacilli are considered to be under non-replicating (NR) stage. In such a condition, bacilli are not only difficult to be detected but also refractory to the standard treatments avoiding their clearance from the in ...
Read Project

 7